Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density.

Autor: Poole KE; Department of Medicine, University of Cambridge and Addenbrooke's Hospital, Cambridge, UK., Treece GM; Department of Engineering, University of Cambridge, Cambridge, UK., Pearson RA; Department of Engineering, University of Cambridge, Cambridge, UK., Gee AH; Department of Engineering, University of Cambridge, Cambridge, UK., Bolognese MA; Bethesda Health Research Center, Bethesda, MD, USA., Brown JP; CHU de Québec Research Centre and Laval University, Quebec City, Canada., Goemaere S; Ghent University Hospital, Ghent, Belgium., Grauer A; Amgen Inc., Thousand Oaks, CA, USA., Hanley DA; University of Calgary, Calgary, Canada., Mautalen C; Centro de Osteopatias Medicas, Buenos Aires, Argentina., Recknor C; United Osteoporosis Centers, Gainesville, GA, USA., Yang YC; Amgen Inc., Thousand Oaks, CA, USA., Rojeski M; Amgen Inc., Thousand Oaks, CA, USA., Libanati C; UCB Pharma, Brussels, Belgium., Whitmarsh T; Institute of Astronomy, University of Cambridge, Cambridge, UK.
Jazyk: angličtina
Zdroj: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 2022 Feb; Vol. 37 (2), pp. 256-264. Date of Electronic Publication: 2021 Dec 16.
DOI: 10.1002/jbmr.4465
Abstrakt: Romosozumab monoclonal antibody treatment works by binding sclerostin and causing rapid stimulation of bone formation while decreasing bone resorption. The location and local magnitude of vertebral bone accrual by romosozumab and how it compares to teriparatide remains to be investigated. Here we analyzed the data from a study collecting lumbar computed tomography (CT) spine scans at enrollment and 12 months post-treatment with romosozumab (210 mg sc monthly, n = 17), open-label daily teriparatide (20 μg sc, n = 19), or placebo (sc monthly, n = 20). For each of the 56 women, cortical thickness (Ct.Th), endocortical thickness (Ec.Th), cortical bone mineral density (Ct.bone mineral density (BMD)), cancellous BMD (Cn.BMD), and cortical mass surface density (CMSD) were measured across the first lumbar vertebral surface. In addition, color maps of the changes in the lumbar vertebrae structure were statistically analyzed and then visualized on the bone surface. At 12 months, romosozumab improved all parameters significantly over placebo and resulted in a mean vertebral Ct.Th increase of 10.3% versus 4.3% for teriparatide, an Ec.Th increase of 137.6% versus 47.5% for teriparatide, a Ct.BMD increase of 2.1% versus a -0.1% decrease for teriparatide, and a CMSD increase of 12.4% versus 3.8% for teriparatide. For all these measurements, the differences between romosozumab and teriparatide were statistically significant (p < 0.05). There was no significant difference between the romosozumab-associated Cn.BMD gains of 22.2% versus 18.1% for teriparatide, but both were significantly greater compared with the change in the placebo group (-4.6%, p < 0.05). Cortical maps showed the topographical locations of the increase in bone in fracture-prone areas of the vertebral shell, walls, and endplates. This study confirms widespread vertebral bone accrual with romosozumab or teriparatide treatment and provides new insights into how the rapid prevention of vertebral fractures is achieved in women with osteoporosis using these anabolic agents. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
(© 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).)
Databáze: MEDLINE
Externí odkaz: